An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis

Phase 3 Completed 401 enrolled Taisho Pharmaceutical Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the long-term safety and efficacy of TS-152 in subjects with Rheumatoid Arthritis who have completed the previous study (TS152-3000-JA study or TS152-3001-JA study).

Timeline

Start: 2019-10-01
Primary completion: 2023-04-28
Completion: 2023-04-28

Publications

Results Tanaka Y, Miyazaki Y, Kawanishi M, Yamasaki H, Takeuchi T. Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis. RMD Open. 2024 Aug 22;10(3):e004480. doi: 10.1136/rmdopen-2024-004480.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TS-152	Unknown	30 mg	Subcutaneous
Subject	TS-152	Unknown	80 mg	Subcutaneous

An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis

Summary

Timeline

Publications

Drugs

Indications